We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Lilly (LLY) Stops Lupus Study, Expects CRL for Olumiant in Eczema
Read MoreHide Full Article
Eli Lilly (LLY - Free Report) and partner Incyte (INCY - Free Report) announced two important updates related to its oral, once-daily JAK1 inhibitor Olumiant (baricitinib) in systemic lupus erythematosus (SLE or lupus) and atopic dermatitis (ADor eczema) indications.
Lilly and Incyte have decided to discontinue the pivotal phase III development program evaluating Olumiant in lupus. The decision is based on data from two pivotal phase III studies — SLE-BRAVE-I and SLE-BRAVE-II — evaluating the drug against placebo across 1500 adult participants with active lupus. While the SLE-BRAVE-I study met its primary endpoint, the SLE-BRAVE-II study failed to achieve the same. In fact, neither of the studies achieved secondary endpoint.
The primary endpoint of both SLE-BRAVE-I and SLE-BRAVE-II studies was to measure the proportion of active lupus patients who achieved an SRI-4 response at week 52. SRI-4 is a composite clinical endpoint to measure the response of treatment using both Olumiant and placebo by comparing the decline in overall disease activity.
Eli Lilly plans to analyze the data from the lupus studies and publish the same at a later date. Currently, Lilly is working with investigators to settle the SLE-BRAVE-X study, a phase III long-term extension study evaluating Olumiant over a period of three years in patients who completed the SLE-BRAVE-I and SLE-BRAVE-II studies.
Shares of Eli Lilly have risen 20.7% in the trailing 12 months in comparison with the industry’s 17.5% rise.
Image Source: Zacks Investment Research
Incyte’s stock has declined 18.4% in the past year in comparison with the industry’s 39.2% decline.
Image Source: Zacks Investment Research
Both Eli Lilly and Incyte also announced an update to their supplemental new drug application (sNDA) with the FDA seeking label expansion for Olumiant in adults with moderate-to-severe AD.
Per the press release, both Eli Lilly and Incyte expect the FDA to issue a complete response letter (CRL) to the sNDA, as Eli Lilly does not have alignment with the FDA on the indicated population.
Please note that Olumiant is already approved in more than 50 countries, including the European Union and Japan, to treat AD in adults who are candidates for systemic therapy.
Currently, Olumiant is approved in the United States for the treatment of adults with moderate-to-severe rheumatoid arthritis (RA). Barictinib is also authorized by the FDA for emergency use in certain hospitalized COVID patients. The FDA is currently reviewing the sNDA seeking full approval in the given indication and a decision is expected in the second quarter.
Please note that AbbVie (ABBV - Free Report) and Pfizer (PFE - Free Report) gained FDA approval for their JAK inhibitor drugs in the United States to treat AD.
Earlier this month, AbbVie announced that the FDA granted label expansion to its JAK inhibitor, Rinvoq, for the treatment of moderate-to-severe AD in adults and children aged 12 years and above who did not respond to treatment with other drugs or when the use of other treatments is not recommended.
This month, Pfizer also announced that the FDA approved its JAK1 inhibitor, Cibinqo (abrocitinib), for the treatment of refractory moderate-to-severe AD in adult patients who did not respond to treatment with other drugs or when the use of other treatments is not recommended.
We note that the FDA remains skeptical toward the JAK inhibitor drugs. Last September, the FDA issued a Drug Safety Communication to include warnings about an increased risk of serious heart-related events, cancer, blood clots and even death, to be added to the label of three JAK inhibitor drugs — including Olumiant, AbbVie’s Rinvoq and Pfizer’s another JAK inhibitor drug, Xeljanz — that are already approved for RA indication.
This FDA decision was based on its review of the final data from the post-marketing safety study of Pfizer’s Xeljanz in RA indication. The FDA limited the use of Xeljanz to certain patients who have not responded to or cannot tolerate one or more TNF blockers. Since AbbVie’s Rinvoq and Olumiant also have a similar mechanism for treatment, the directive was extended to them as well.
Zacks Rank
Eli Lilly currently carries a Zacks Rank #2 (Buy) while Incyte holds a Zacks Rank #4 (Sell) at present.
Image: Bigstock
Lilly (LLY) Stops Lupus Study, Expects CRL for Olumiant in Eczema
Eli Lilly (LLY - Free Report) and partner Incyte (INCY - Free Report) announced two important updates related to its oral, once-daily JAK1 inhibitor Olumiant (baricitinib) in systemic lupus erythematosus (SLE or lupus) and atopic dermatitis (ADor eczema) indications.
Lilly and Incyte have decided to discontinue the pivotal phase III development program evaluating Olumiant in lupus. The decision is based on data from two pivotal phase III studies — SLE-BRAVE-I and SLE-BRAVE-II — evaluating the drug against placebo across 1500 adult participants with active lupus. While the SLE-BRAVE-I study met its primary endpoint, the SLE-BRAVE-II study failed to achieve the same. In fact, neither of the studies achieved secondary endpoint.
The primary endpoint of both SLE-BRAVE-I and SLE-BRAVE-II studies was to measure the proportion of active lupus patients who achieved an SRI-4 response at week 52. SRI-4 is a composite clinical endpoint to measure the response of treatment using both Olumiant and placebo by comparing the decline in overall disease activity.
Eli Lilly plans to analyze the data from the lupus studies and publish the same at a later date. Currently, Lilly is working with investigators to settle the SLE-BRAVE-X study, a phase III long-term extension study evaluating Olumiant over a period of three years in patients who completed the SLE-BRAVE-I and SLE-BRAVE-II studies.
Shares of Eli Lilly have risen 20.7% in the trailing 12 months in comparison with the industry’s 17.5% rise.
Incyte’s stock has declined 18.4% in the past year in comparison with the industry’s 39.2% decline.
Both Eli Lilly and Incyte also announced an update to their supplemental new drug application (sNDA) with the FDA seeking label expansion for Olumiant in adults with moderate-to-severe AD.
Per the press release, both Eli Lilly and Incyte expect the FDA to issue a complete response letter (CRL) to the sNDA, as Eli Lilly does not have alignment with the FDA on the indicated population.
Please note that Olumiant is already approved in more than 50 countries, including the European Union and Japan, to treat AD in adults who are candidates for systemic therapy.
Currently, Olumiant is approved in the United States for the treatment of adults with moderate-to-severe rheumatoid arthritis (RA). Barictinib is also authorized by the FDA for emergency use in certain hospitalized COVID patients. The FDA is currently reviewing the sNDA seeking full approval in the given indication and a decision is expected in the second quarter.
Please note that AbbVie (ABBV - Free Report) and Pfizer (PFE - Free Report) gained FDA approval for their JAK inhibitor drugs in the United States to treat AD.
Earlier this month, AbbVie announced that the FDA granted label expansion to its JAK inhibitor, Rinvoq, for the treatment of moderate-to-severe AD in adults and children aged 12 years and above who did not respond to treatment with other drugs or when the use of other treatments is not recommended.
This month, Pfizer also announced that the FDA approved its JAK1 inhibitor, Cibinqo (abrocitinib), for the treatment of refractory moderate-to-severe AD in adult patients who did not respond to treatment with other drugs or when the use of other treatments is not recommended.
We note that the FDA remains skeptical toward the JAK inhibitor drugs. Last September, the FDA issued a Drug Safety Communication to include warnings about an increased risk of serious heart-related events, cancer, blood clots and even death, to be added to the label of three JAK inhibitor drugs — including Olumiant, AbbVie’s Rinvoq and Pfizer’s another JAK inhibitor drug, Xeljanz — that are already approved for RA indication.
This FDA decision was based on its review of the final data from the post-marketing safety study of Pfizer’s Xeljanz in RA indication. The FDA limited the use of Xeljanz to certain patients who have not responded to or cannot tolerate one or more TNF blockers. Since AbbVie’s Rinvoq and Olumiant also have a similar mechanism for treatment, the directive was extended to them as well.
Zacks Rank
Eli Lilly currently carries a Zacks Rank #2 (Buy) while Incyte holds a Zacks Rank #4 (Sell) at present.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.